Does high epoetin dosage affect survival in elderly hemodialysis patients?
In elderly hemodialysis patients, epoetin dosages >30,000 U/wk do not appear to confer additional harm or benefit regarding survival when adjusting for time-dependent confounding by indication.
BACKGROUND AND OBJECTIVES: The common finding that low achieved hemoglobin in observational studies and high target hemoglobin in randomized trials each were associated with increased mortality and high epoetin dosage has suggested the possibility that high epoetin dosage might explain the increased mortality risk. DESIGN, SETTING, PARTICIPANTS, 95% confidence interval CI) was 0.90 (0.52 to 1.54) for 40,000 U/wk. In contrast, conventional unweighted models, which do not adequately adjust for time-dependent confounding by indication, indicated an association between high cumulative average epoetin dosage and increased mortality. CONCLUSIONS: Our findings suggest that, on average, epoetin dosages >30,000 U/wk do not confer additional harm or benefit in elderly hemodialysis patients.
Zhang et al. (Sun,) studied this question.